ClinicalTrials.gg
CompletedNCT02686619Updated Feb 19, 2016

Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients

A Phase 3 interventional study of Cyclosporine and Daclizumab in Renal Transplantation, sponsored by Hoffmann-La Roche. Completed at 17 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-02-19.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
237
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This multicentre, prospective, randomized, open-label study will compare the safety and efficacy of mycophenolate mofetil with delayed introduction of sirolimus and discontinuation of cyclosporine, with those of mycophenolate mofetil and long term continuation of cyclosporine in renal transplant recipients receiving daclizumab (Zenapax) as induction treatment and followed by 8 month treatment with corticosteroids. The anticipated time on study treatment is 12 months. Participants who will complete the initial 12-month study and who will provide written informed consent will be eligible to participate in a 60-month follow-up phase.

02

Conditions studied

  • Renal Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Receipt of a first cadaveric kidney graft
  • Antilymphocyte antibodies and panel reactive antibodies (PRA) less than 30 percent (%) (historical peak and/or current value)
  • Cold ischaemia time less than or equal to 36 hours

Exclusion Criteria:

  • Kidney from a living donor; donor greater than (>) 65 years of age; second renal graft, or more; or multiple organ transplant
  • Known to any of the drugs in the study or their components
  • History of cancer or during previous 5 years, other than successfully treated spinocellular or basal cell cancer
  • Participant presenting, on inclusion, either symptoms suggestive of active gastroduodenal ulcer, or gastroduodenal ulcer confirmed by fibroscopy and , and requiring treatment
  • Participant with severe hyperlipidaemia
  • Pregnant woman or nursing mother

Exclusion Criteria for Follow-up Phase:

  • Episode of acute rejection greater than or equal to grade I (Banff classification)
  • Estimated (CrCl) at week 12 less than (\<) 40 milliliter per minute (mL/min) (Cockcroft-Gault formula)
  • Serum creatinine variations >30% during the 15 days before randomization
  • Proteinuria >1 gram/24 hour, or mean mycophenolate mofetil dose \< 1.5 gram/day during the week before randomization
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
237 participants (actual)

Study arms

  • Active comparator
    Mycophenolate Mofetil + Cyclosporine

    Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.

    Drug: Cyclosporine · Drug: Daclizumab · Drug: Mycophenoate Mofetil · Drug: Prednisolone

  • Experimental
    Mycophenolate Mofetil + Sirolimus

    Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.

    Drug: Cyclosporine · Drug: Daclizumab · Drug: Mycophenoate Mofetil · Drug: Prednisolone · Drug: Sirolimus

Interventions

  • Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.

    Also known as: Neoral

  • Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.

    Also known as: Zenapax

  • Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.

    Also known as: CellCept

  • Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.

    Also known as: Solupred

  • Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.

    Also known as: Rapamycin

06

What researchers measure

Primary outcomes

  1. Creatinine Clearance Calculated and Corrected According to Cockcroft Gault at Month 60

    Time frame: 60 months

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to approximately 12 months

  3. Number of Participants With Serious Adverse Events (SAEs)

    Time frame: From 12 months up to 60 months

  4. Creatinine Clearance Calculated and Corrected According to Cockcroft Gault at Week 52

    Time frame: 52 weeks

  5. Number of Participants With Cancers and Lymphoproliferative Syndromes

    Time frame: Up to approximately 12 months

  6. Number of Participants With Premature Discontinuations due to Adverse Events (AEs)

    Time frame: Up to approximately 12 months

  7. Change From Baseline in 24-Hour Urinary Protein at Week 52

    Time frame: 52 weeks

Secondary outcomes

  1. Mean Inverse Creatinine Concentration

    Time frame: Week 4, 8, 12, 14, 16, 26, 39, and 52

  2. Creatinine Clearance Calculated and Corrected According to Cockcroft-Gault

    Time frame: Week 4, 8, 12, 14, 16, 26, 39, and 52

  3. Glomerular Filtration Rate (GFR) Measured by Iohexol Clearance

    Time frame: Baseline, Week 52

  4. Number of Participants with Response to Treatment, Defined as Creatinine Clearance >/=60 mL/min at Week 52

    Time frame: Week 52

  5. Number of Participants With Treated Rejections

    Time frame: Baseline up to Week 52

  6. Mean Serum Creatinine Concentration

    Time frame: Week 4, 8, 12, 14, 16, 26, 39, and 52

  7. Number of Participants With Biopsy-proven Acute Rejections

    Time frame: Baseline up to Month 60

  8. Number of Participants With Histologic Evaluation of the Graft

    Time frame: Week 52

  9. Number of Participants Who Were Alive

    Time frame: Month 60

  10. Number of Participants With Graft Survival

    Time frame: Month 60

07

Study locations

17 sites
  • Angers, 49933, France
  • Caen, 14033, France
  • Clermont-ferrand, 63000, France
  • La Tronche, 38700, France
  • Lille, 59037, France
  • Limoges, 87042, France
  • Lyon, 69437, France
  • Paris, 75018, France
  • Paris, 75475, France
  • Paris, 75743, France
  • Poitiers, 86021, France
  • Reims, 51092, France
  • Rennes, 35033, France
  • Rouen, 76031, France
  • Salouel, 80480, France
  • Strasbourg, 67091, France
  • Tours, 37044, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2016
First posted
Feb 19, 2016
Start
Nov 2004
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Last update
Feb 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02686619
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 19, 2016
Start date
Nov 2004
Primary completion
Jan 2011
Completion
Jan 2011
Last update
Feb 19, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion